Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (Nasdaq: CERT) is a global leader in biosimulation software, technology, and consulting services that transform traditional drug discovery and development processes. By leveraging cutting-edge modeling and simulation tools, Certara helps biopharmaceutical companies, academic institutions, and regulatory agencies accelerate the development of life-saving medicines while reducing costs and improving patient outcomes. The company's core mission is to optimize drug development through model-informed approaches, enabling its clients to enhance the probability of regulatory and commercial success.
Business Model and Revenue Streams
Certara operates a diversified business model that combines software licensing, consulting services, and strategic partnerships. Its flagship products, such as the Phoenix™ pharmacokinetic/pharmacodynamic (PK/PD) platform and Certara Cloud, provide a unified ecosystem for drug developers to manage, analyze, and model clinical trial data. These solutions are offered on a subscription or licensing basis, ensuring recurring revenue streams. Additionally, Certara's consulting services, which include regulatory science and quantitative systems pharmacology (QSP) expertise, generate significant revenue by addressing complex drug development challenges for its clients. The company also collaborates with regulatory agencies like the U.S. FDA, Japan PMDA, and China NMPA, further solidifying its authority in the field.
Industry Context and Competitive Landscape
Certara operates within the highly specialized niche of model-informed drug development (MIDD), a critical segment of the broader healthcare and life sciences industry. This field is becoming increasingly important as the pharmaceutical sector faces mounting pressure to reduce clinical trial failures and bring new drugs to market faster. Certara's competitors include other biosimulation software providers, contract research organizations (CROs), and in-house solutions developed by large pharmaceutical companies. However, Certara differentiates itself through its comprehensive suite of interoperable software, deep scientific expertise, and long-standing relationships with regulatory bodies. Its solutions are trusted by 15 of the top 30 biopharmaceutical companies globally, underscoring its market leadership.
Core Technologies and Innovations
Certara's technological ecosystem is built around advanced biosimulation and data analytics tools designed to streamline the drug development lifecycle. The Certara Cloud platform, for instance, integrates multiple software solutions into a single, user-friendly interface, allowing clients to access predictive models and analyze clinical trial results seamlessly. The Phoenix platform, widely regarded as the gold standard in PK/PD modeling, is used by leading pharmaceutical companies and regulatory agencies to evaluate drug candidates. Additionally, Certara's expertise in virtual trials and mechanistic modeling enables its clients to optimize dosing strategies, reduce reliance on animal studies, and accelerate regulatory approvals.
Global Reach and Client Base
With a presence in the Americas, EMEA, and Asia-Pacific regions, Certara serves a diverse and global client base. Its clients include over 2,400 biopharmaceutical companies, leading academic institutions, and regulatory agencies across 66 countries. This extensive reach highlights Certara's ability to address the unique challenges of different markets while maintaining a consistent standard of excellence. The company's innovative solutions have been instrumental in expediting drug approvals and improving health outcomes worldwide.
Challenges and Opportunities
While Certara's technologies offer significant advantages, the company operates in a competitive and rapidly evolving industry. Challenges include the need to continually innovate, maintain regulatory compliance, and address the growing complexity of drug development. However, Certara is well-positioned to capitalize on industry trends such as the increasing adoption of model-informed drug development and the shift toward personalized medicine. Its ongoing investments in technology, such as the phased rollout of Certara Cloud, demonstrate its commitment to staying at the forefront of the industry.
Conclusion
Certara, Inc. is a cornerstone of innovation in the pharmaceutical and biotechnology sectors, providing indispensable tools and expertise that accelerate the drug development process. By combining advanced biosimulation software with unparalleled scientific and regulatory knowledge, Certara empowers its clients to bring safer, more effective medicines to market faster. Its strategic focus on innovation, global reach, and trusted relationships with regulatory agencies positions it as a vital partner in the quest to improve global health outcomes.
Certara, a leader in biosimulation, announced on December 21, 2021, that the FDA has renewed and expanded its licenses for more than 400 user licenses of Certara's Simcyp and Phoenix software across 12 divisions. This software plays a critical role in drug development, helping the FDA analyze investigational therapies, new drug applications, and generic applications. The renewal indicates the FDA's growing reliance on Certara's tools, which are used by 37 of the top 40 biopharmaceutical companies. This expansion reflects Certara's influential position in ensuring the safety and efficacy of medicines.
Certara has announced the release of Pinnacle 21 Enterprise 5.1.0, enhancing its capabilities for biopharmaceutical clients. This update focuses on improving clinical trial data preparation for regulatory submissions, aligning with CDISC standards. The new features include support for the Define-XML 2.1 standard and an analytics module for summarizing portfolio performance. Major biopharmaceutical companies and regulatory bodies, such as the US FDA, utilize this software, indicating its critical role in accelerating time-to-market for medical products.
Certara, a leader in biosimulation, will host an Investor Day on December 15, 2021, from 3:00 PM to 6:00 PM ET in New York City. During this event, the management team will share updates on the company's strategy, software, and financial guidance for 2022. A demonstration of the Simcyp™ Simulator will also take place. The event will be available via a live video webcast on Certara's Investor Relations website, and a replay will be accessible for two weeks post-event.
Certara, a leader in biosimulation, announced the release of Simcyp Simulator Version 21, enhancing its population-based modeling platform. This tool aids in drug development by predicting dosing and drug-drug interactions without extensive clinical trials. The simulator has informed over 250 label claims for 85+ novel drugs approved by the FDA. New features include updates for renal and hepatic models, expanded brain models, and a broadened compound library. These advancements align with FDA guidance, facilitating faster drug approvals.
Certara, Inc. (Nasdaq: CERT) has launched D360 version 21.5, enhancing its scientific informatics software for biomedical research. This update improves efficiency in analyzing small molecules and biologic drugs, facilitating quicker, higher-confidence decision-making in drug development. Key new features include support for biologic drug sequence clustering, transformation analysis for small molecules, accelerated workflows, and advanced data visualization. D360 is utilized by over 6,000 scientists at top biopharmaceutical firms, reaffirming Certara's commitment to optimizing drug discovery processes.
Certara, Inc. (Nasdaq: CERT) has closed its public offering of 10,000,000 shares at $31.00 each, undertaken by existing stockholders. The underwriters were granted a 30-day option for an additional 1,500,000 shares. Certara will not receive any proceeds from this sale. The offering was led by Jefferies, Morgan Stanley, and BofA Securities, with other firms participating. A registration statement relating to these securities was approved by the SEC. Full prospectus details are available upon request from the underwriting firms.
Certara, a leader in biosimulation, announced the pricing of an underwritten public offering of 10 million shares at $31.00 each, solely by existing stockholders. The underwriters have a 30-day option to purchase an additional 1.5 million shares. Certara will not receive proceeds from this offering, which is expected to close on November 22, 2021. This offering is managed by Jefferies, Morgan Stanley, and BofA Securities, among others. A registration statement has been declared effective by the SEC.
Certara has announced a proposed underwritten public offering of 10 million shares of its common stock by certain selling stockholders, as per the registration statement filed with the Securities and Exchange Commission. The underwriters will have a 30-day option to purchase an additional 1.5 million shares. Certara will not receive any proceeds from this offering. The underwriting group includes Jefferies, Morgan Stanley, and BofA Securities. A preliminary prospectus has been filed but is subject to completion and will not be effective until registration formalities are met.
Certara, Inc. (Nasdaq: CERT) reported third-quarter 2021 revenues of $73.9 million, a 23% increase from the previous year. However, the company incurred a net loss of $1.8 million compared to a net income of $1.2 million in Q3 2020. Adjusted EBITDA rose 28% to $26.1 million. Certara announced the completion of its $250 million acquisition of Pinnacle 21 and raised its full-year guidance, forecasting revenue between $288 million and $291 million, adjusted EBITDA of $106 million to $108 million, and adjusted diluted EPS between $0.22 and $0.26.
Certara, Inc. (Nasdaq: CERT) has announced the appointment of James E. Cashman III as Chairman of the Board, effective December 1, 2021. He will succeed Sherilyn McCoy, who is stepping down to focus on other commitments. Cashman, who has served on Certara's Board since 2018, previously led ANSYS, growing its revenue from $50 million to over $1 billion. His expertise in simulation-driven product development is expected to strengthen Certara's innovation and growth strategy. The company specializes in biosimulation technologies enhancing drug development.
FAQ
What is the current stock price of Certara (CERT)?
What is the market cap of Certara (CERT)?
What does Certara, Inc. do?
Who are Certara's main clients?
What are Certara's key products?
How does Certara differentiate itself from competitors?
What industries does Certara operate in?
How does Certara help reduce clinical trial costs?
What is Certara Cloud?
What is model-informed drug development (MIDD)?
What regulatory agencies does Certara work with?
Where is Certara headquartered?
